GeneDx is trading 4.17% lower at $68.54, with no verified company-specific announcement explaining the decline. - The company published newborn genomic-screening research on October 7; the release does not identify a negative business or financial development. - The biotech-sector ETF was reported down 2.50% during the session, while broader major indexes were also lower. - Available evidence does not establish a specific catalyst for GeneDx’s additional weakness.